GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients

March 8-11, 2020; Boston, Massachusetts
Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 163 KB
Released: March 13, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Slides from Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Free slides from CCO featuring data on racial inequities in HIV care in BIPOC communities and strategies to combat racial disparities in HIV

person default Solange L. Baptiste, ScM Rageshri Dhairyawan, MBBS, BSc, FCRP, DipGUM, DipHIV, DFSRH person default Samantha V. Hill, MD, MPH David Malebranche, MD, MPH Released: January 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings